Chimerix to drop development of brincidofovir for Ebola

2 February 2015

US antiviral biopharma company Chimerix (Nasdaq: CMRX) says that, after discussion with the US Food and Drug Administration, the company is ceasing further participation in all current and future clinical studies of brincidofovir (CMX001) for Ebola virus disease (EVD).

This includes the study announced in December in Liberia sponsored by investigators at the University of Oxford and the supportive Phase II study of brincidofovir for EVD, Study 205. Chimerix’ shares fell 4% to $38.50 in late trading on Friday.

Over the last several weeks the number of new cases of confirmed EVD in Liberia has decreased significantly, with only a handful of patients enrolled to date in the single-arm study of brincidofovir led by the University of Oxford and ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) with operational support from Medecins Sans Frontieres (MSF).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK